SL3-3 is a highly T-lymphomagenic murine retrovirus in which the transcriptional enhancer is a major oncogenic determinant. Here, we describe an SL3-3 enhancer variant that induced T-cell lymphomas in all inoculated mice with a shorter latency period than wild-type SL3-3. The enhancer repeat region of this variant contains two deletions encompassing the nuclear factor 1 binding sites in addition to an additional intact enhancer repeat element. Tumors induced by this variant were T-cell lymphomas, as indicated by T-cell receptor rearrangements, and contained the input provirus enhancer regions. The variant was the result of mutation of specific transcription factor binding sites in the viral enhancer, isolation of rare second-site enhancer variants from the resulting induced tumors, and subsequent restoration of the original first-site mutations of one such variant. We have termed this process assisted molecular evolution.
SL3-3 is a highly lymphomagenic, non-oncogene-bearing murine leukemia virus (MLV). It induces the formation of T-cell lymphomas when inoculated into susceptible newborn mice, with a latency period of between 2 and 6 months depending on the mouse strain. As for other MLVs, a major determinant of the oncogenic potential of SL3-3 has been shown to reside in the transcriptional enhancer, which consists of densely packed binding sites for several transcription factors. In SL3-3, the enhancer is organized as 72 directly repeated base pairs followed by a third repetition of the first 34 bp (Fig. 1) . A region highly conserved among the majority of MLVs which has previously been termed the enhancer framework (5) is also present in the SL3-3 enhancer repeats. It includes binding sites for the AML1 transcription factor family (14, 16) , nuclear factor 1 (NF1) (3, 11) , members of the Ets transcription factor family (10, 15) , basic helix-loop-helix factor transcription factors (8, 9) , and the glucocorticoid receptor (2) . Furthermore, upstream of this region, the SL3-3 enhancer contains a binding site for the c-Myb transcription factor (10, 15) and an additional site, denoted site II, for the AML1 factor complex (14, 16) . The roles of several individual factor binding sites have been examined in pathogenicity studies of viruses in which specific mutations have been introduced into the enhancer. These studies have shown AML1 site I (6, 7) and the Myb site (10) to be of primary importance, whereas the Ets site is only slightly important (10), the NF1 site is dispensable (3), and AML1 site II is only important when AML1 site I is simultaneously mutated (4, 6) .
In a previous study investigating the lymphomagenicity of AML1 binding site mutants of SL3-3 (6), we noted rare occasions of second-site alterations in the viral enhancers of the proviruses in the resulting murine tumors. Although independent, such enhancer alterations all followed a common theme involving deletions of the area in the enhancer region containing the NF1 binding site and, in most cases, also the addition of extra 72-bp repeat elements (3) . When tested in a transient reporter assay in a T-cell line, these altered enhancer repeats were shown to act as stronger enhancers than the mutant structures from which they evolved (3). Furthermore, the pathogenic potentials of an SL3-3 virus variant containing one of these altered enhancer regions and of the AML1 site mutant from which it evolved were investigated (4). Whereas the latter induced non-T-cell tumors after a highly extended latency period, the enhancer variant with the second-site alterations induced T-cell lymphomas with a mean latency period half that length. This showed that the altered variant was generated as a result of selection for a more highly pathogenic virus variant in the course of the process of pathogenesis (4) . An SL3-3 variant with increased pathogenicity. This prompted us to ask what the pathogenicity of SL3-3 variants carrying these alterations in their enhancers in the context of functional AML1 sites would be. To investigate this matter, two previously described SL3-3 enhancer variant constructs (3) in which the originally introduced mutations had been restored, but the NF1 site region deletions had been maintained, were used. These variants carried two identical deletions of 18 bp accompanied by 1-bp substitutions in the enhancer repeats. In addition, one of the variants carried an extra intact 72-bp repeat element like that found in the original tumor-derived variant (Fig. 1 ). These variant enhancer regions were inserted into plasmids encoding molecular clones of SL3-3, and infectious viruses were generated by transfection of both variant clones into NIH 3T3 fibroblasts; this was followed by direct sequencing of U3 regions of PCR-amplified proviruses to confirm the viral structure, as previously described (4). Pathogenicity experiments were performed by injecting between 10 6 and 10 7 infectious particles of each variant and wild-type SL3-3 into newborn mice of the inbred NMRI strain. Deceased mice were autopsied and diagnosed according to previously described criteria (12) . The incidence of lymphoma development in the infected mice is shown in Fig. 2 and Table 1 . All mice developed tumors within 3 months. The lymphomas induced by the variant with the two 18-bp deletions plus an intact 72-bp repeat element, denoted SL3(2⌬18-3 1/2), developed within a latency period that was 2 weeks shorter than for those induced by wild-type SL3-3, denoted SL3(WT). This difference is statistically significant (P Ͻ 0.0001 by the log rank test). In contrast, lymphomas induced by the variant with the two 18-bp deletions, but without the additional repeat element, denoted SL3(2⌬18-2 1/2), developed after a slightly longer latency period than for those induced by SL3(WT). This difference between the wild type and SL3(2⌬18-2 1/2) is not statistically significant (P Ͻ 0.092 by the log rank test). We note that the inbred NMRI mice (4) used for these experiments were more susceptible to lymphoma induction by SL3-3 than the random-bred NMRI mice used in previous studies (3, 6) , a fact which tends to narrow the differences in lymphoma latency periods between different enhancer variants (4). Lymphoma and provirus characterization. Histological examination of the tumors showed that they were all large-cell lymphoblastic malignant lymphomas. No differences in the tumor types induced by SL3(WT) and the two variants were found. To confirm that the tumors induced by the SL3(2⌬18-3 1/2) variant were T-cell lymphomas, Southern blotting was performed. To this end, genomic DNAs were prepared from tumor tissues and digested with HindIII. Two probes, designed to recognize rearrangements in either the J1 or the J2 region of the T-cell receptor (TCR) ␤-chain locus (1), were used. All of the eight tumors randomly chosen for analysis were found to contain clonal rearrangements of the TCR ␤-chain locus (Fig.  3) , verifying that they were T lymphomas. To determine if the variant enhancers had been subject to rearrangements in the course of the pathogenic process, we PCR amplified 5Ј proviral long terminal repeat regions from DNAs prepared from the tumors and sequenced the U3 regions as described earlier (3). As previously found for tumors induced by SL3-3 (3, 4, 7, 10), more than half contained proviral structures with alterations in the number of enhancer repeat elements, and these altered structures were coexisting with the input proviral structures. In some cases, various point mutations were also present in the enhancer regions, but major alterations were not found. Apart from the repeat-number fluctuations, both variants and the wild type thus seemed to have been genetically stable during the pathogenic process.
Assisted molecular evolution. The description of an SL3-3 enhancer variant which induces lymphomas after a shorter latency period than that of the wild type is interesting in light of the rapid onset of disease induced by wild-type SL3-3. The result emphasizes the overall importance of the enhancer as a determinant of pathogenesis. In addition, the existence of an enhancer variant with greater pathogenicity demonstrates that the native enhancer of SL3-3 does not have the maximal lymphomagenic potential, although SL3-3 supposedly has been strongly selected for its tumorigenicity. Also, the process by which the more highly pathogenic variant was generated emphasizes the dynamic potential of the enhancer. This process, which we have termed assisted molecular evolution, consisted of three steps. First, mutations in specific transcription factor binding sites in the enhancer were introduced. Second, mice were infected with the mutants, and second-site enhancer alterations selected for in vivo during the pathogenic process were isolated from resulting tumors. Third, the original firstsite mutations were reversed and the pathogenicity of one such new variant was tested.
In tumors induced by wild-type SL3-3, we have not detected major alterations in the enhancer structure apart from the frequently occurring repeat-number fluctuations. However, in tumors induced by AML1 site mutants of SL3-3, alterations in the enhancer have been found in a few cases (3) . Moreover, the frequency of the alterations appears to rise with the impact of the mutations on viral pathogenicity, as measured by the increase in latency periods of disease induction (4). Thus, it seems that by experimentally reducing the pathogenicity of SL3-3, a selection for new, more highly pathogenic variants arising during the pathogenic process is favored. This view is further supported by the increased pathogenicity of the variant described here.
The experiments performed here did not address the question of the pathogenic strength of an SL3-3 variant with 3 1/2 enhancer repeats lacking the NF1 site region deletions. However, the previous observation of proviral structures containing the NF1 site deletions in independent tumors (3) indicates that the combination of these deletions and the additional repeats is of importance for the pathogenic strength of the variants.
We have previously found that an SL3-3 enhancer variant with mutations in all three NF1 binding sites does not have a reduced pathogenic potential (3). As noted earlier, this is in contrast to the situation regarding Moloney MLV, in which mutations of the NF1 sites significantly increased the disease latency periods (13) . The results for the SL3(2⌬18-2 1/2) variant described here show that the entire binding site regions of two of the three NF1 sites-i.e., a significant part of the enhancer framework area-can be deleted without notably impairing the pathogenic potential of the virus. Thus, this enhancer variant adds to the evidence indicating that the NF1 site enhancer region is dispensable for or negatively contributes to the lymphomagenic potential of SL3-3 (3, 4) . Furthermore, the increased pathogenicity of the SL3(2⌬18-3 1/2) variant shows that the originally introduced ATC mutations (Fig. 1) at least partly function independently of the NF1 site regions. However, the precise function of these regions of the enhancer still remains to be established.
